Skip to main content

Correction to: Chronomedicine and type 2 diabetes: shining some light on melatonin

The Original Article was published on 16 December 2016

Correction to: Diabetologia

https://doi.org/10.1007/s00125-016-4175-1

The authors have been made aware that the following sentence is incorrect: ‘Like IIK7, both ramelteon and tasimelteon have a greater affinity for the MT2 receptor.’ In fact, ramelteon has a greater affinity for MT1 than MT2, whereas tasimelteon, like IIK7, preferentially binds to the MT2 receptor [1]. The authors apologise for this error.

Reference

  1. Williams WP III, McLin DE III, Dressman MA, Neubauer DN (2016) Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. Pharmacotherapy 36:1028–1041

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael T. Sellix.

Additional information

The online version of the original article can be found at https://doi.org/10.1007/s00125-016-4175-1

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Forrestel, A.C., Miedlich, S.U., Yurcheshen, M. et al. Correction to: Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia 61, 1237 (2018). https://doi.org/10.1007/s00125-018-4577-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00125-018-4577-3